Home » Authors » Aaron Lorenzo

Aaron Lorenzo

Articles

ARTICLES

MedImmune Sells $500M In Notes, Reports Plan For Stock Buyback

July 11, 2003

By Aaron Lorenzo

PDL Sells $250M In Notes To Pay Down Old Debt, Fund Expansion

July 10, 2003

By Aaron Lorenzo

Protein Design Labs Inc. is planning to replace old debt with new after gaining $250 million through the sale of convertible subordinated notes in a private placement. (BioWorld Today)

PDL Sells $250M In Notes To Pay Down Old Debt, Fund Expansion

July 10, 2003

By Aaron Lorenzo

Protein Design Labs Inc. is planning to replace old debt with new after gaining $250 million through the sale of convertible subordinated notes in a private placement. (BioWorld Today)

AEterna To Raise C$35.6M Upon Entering Bought-Deal Agreement

July 9, 2003

By Aaron Lorenzo

XOMA Regains Full Rights To Neuprex As Baxter Pulls Out

July 9, 2003

By Aaron Lorenzo

XOMA Regains Full Rights To Neuprex As Baxter Pulls Out

July 9, 2003

By Aaron Lorenzo

AEterna To Raise C$35.6M Upon Entering Bought-Deal Agreement

July 9, 2003

By Aaron Lorenzo

NexMed Raises $10.5M Through Private Sale Of Common Shares

July 8, 2003

By Aaron Lorenzo

Cellegy Stock Slides After FDA Issues Non-Approvable Letter

July 8, 2003

By Aaron Lorenzo

Cellegy Stock Slides After FDA Issues Non-Approvable Letter

July 8, 2003

By Aaron Lorenzo

View All Articles by Aaron Lorenzo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 6, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...